30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now
United States Biotechnology & Medical Research

OncoMed Pharmaceuticals Inc (OMED)

Track

Stock chart
Ticker: OMED Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
Gurney Austin
See Remarks
1 sale — total 6,669 USD
Sale 24 Dec 2018
Value US$4,213,318.30 | Price 52.20 | Shares 47,495
Sale 10 Oct 2018
Value US$1,028,783.71 | Price 320.79 | Shares 48,320
Sale 10 Oct 2018
Value US$1,863.27 | Price 2.01 | Shares 927
Sale 10 Oct 2018
Value US$2,323.56 | Price 2.01 | Shares 1,156
Sale 10 Oct 2018
Value US$2,335.12 | Price 2.02 | Shares 1,156
Sale 10 Oct 2018
Value US$2,323.56 | Price 2.01 | Shares 1,156
Sale 9 Oct 2018
Value US$3,589.33 | Price 2.13 | Shares 1,686
Planned sale 9 Oct 2018
Value US$2,616.30 | Price 2.13 | Shares 1,229
Planned sale 9 Oct 2018
Value US$3,589.33 | Price 2.13 | Shares 1,686
Planned sale 9 Oct 2018
Value US$4,887.95 | Price 2.13 | Shares 2,296
Sale 9 Oct 2018
Value US$3,589.16 | Price 2.13 | Shares 1,686
Sale 24 Apr 2018
Value US$10,848.17 | Price 2.68 | Shares 4,051
Sale 24 Apr 2018
Value US$12,202.28 | Price 2.68 | Shares 4,557
Sale 24 Apr 2018
Value US$10,847.77 | Price 2.68 | Shares 4,051
Sale 24 Apr 2018
Value US$13,554.52 | Price 2.68 | Shares 5,062
Sale 24 Apr 2018
Value US$10,847.77 | Price 2.68 | Shares 4,051
Sale 10 Oct 2017
Value US$5,098.64 | Price 4.24 | Shares 1,202
Sale 10 Oct 2017
Value US$195.98 | Price 4.26 | Shares 46
Sale 10 Oct 2017
Value US$5,098.64 | Price 4.24 | Shares 1,202
Sale 10 Oct 2017
Value US$196.42 | Price 4.27 | Shares 46
Sale 10 Oct 2017
Value US$5,709.46 | Price 4.24 | Shares 1,346
Sale 10 Oct 2017
Value US$221.58 | Price 4.26 | Shares 52
Sale 10 Oct 2017
Value US$5,098.64 | Price 4.24 | Shares 1,202
Sale 10 Oct 2017
Value US$196.42 | Price 4.27 | Shares 46
Sale 10 Oct 2017
Value US$5,098.64 | Price 4.24 | Shares 1,202
Sale 10 Oct 2017
Value US$195.98 | Price 4.26 | Shares 46
Buy 5 Jun 2017
Value US$34,588.00 | Price 3.46 | Shares 10,000
Sale 26 May 2017
Value US$11,927.20 | Price 3.70 | Shares 3,222
Sale 26 May 2017
Value US$23,536.04 | Price 3.70 | Shares 6,358
Buy 25 May 2017
Value US$116,638.80 | Price 3.37 | Shares 34,614
Sale 24 May 2017
Value US$5,376.76 | Price 3.72 | Shares 1,447
Sale 24 May 2017
Value US$10,601.18 | Price 3.72 | Shares 2,853
Buy 23 May 2017
Value US$71,000.00 | Price 3.55 | Shares 20,000
Sale 19 May 2017
Value US$9,323.57 | Price 3.70 | Shares 2,519
Sale 19 May 2017
Value US$18,388.06 | Price 3.70 | Shares 4,968
Buy 16 May 2017
Value US$82,060.59 | Price 3.49 | Shares 23,507
Sale 16 May 2017
Value US$8,313.36 | Price 3.58 | Shares 2,321
Sale 16 May 2017
Value US$16,401.06 | Price 3.58 | Shares 4,579
Sale 4 Apr 2017
Value US$51,731.38 | Price 9.06 | Shares 5,711
Sale 4 Apr 2017
Value US$381.59 | Price 8.87 | Shares 43
Planned sale 4 Apr 2017
Value US$51,731.38 | Price 9.06 | Shares 5,711
Planned sale 4 Apr 2017
Value US$381.29 | Price 8.87 | Shares 43
Sale 4 Apr 2017
Value US$38,805.33 | Price 9.06 | Shares 4,284
Sale 4 Apr 2017
Value US$283.98 | Price 8.87 | Shares 32
Planned sale 4 Apr 2017
Value US$58,198.94 | Price 9.06 | Shares 6,425
Planned sale 4 Apr 2017
Value US$425.62 | Price 8.87 | Shares 48
Planned sale 4 Apr 2017
Value US$51,731.38 | Price 9.06 | Shares 5,711
Planned sale 4 Apr 2017
Value US$381.29 | Price 8.87 | Shares 43
Planned sale 4 Apr 2017
Value US$51,731.38 | Price 9.06 | Shares 5,711
Planned sale 4 Apr 2017
Value US$381.29 | Price 8.87 | Shares 43
Planned sale 15 Mar 2017
Value US$66,520.00 | Price 10.00 | Shares 6,652
Planned sale 6 Jan 2017
Value US$181,957.04 | Price 8.52 | Shares 21,369
Planned sale 5 Jan 2017
Value US$174,601.83 | Price 8.17 | Shares 21,369
Planned sale 3 Jan 2017
Value US$97,448.06 | Price 7.64 | Shares 12,763
Planned sale 3 Jan 2017
Value US$70,044.70 | Price 7.63 | Shares 9,175
Planned sale 16 Nov 2016
Value US$123,608.75 | Price 9.89 | Shares 12,500
Planned sale 11 Jan 2016
Value US$50,021.00 | Price 20.01 | Shares 2,500
Sale 7 Jan 2016
Value US$21.33 | Price 21.33 | Shares 1
Sale 7 Jan 2016
Value US$21.33 | Price 21.33 | Shares 1
Sale 7 Jan 2016
Value US$21.33 | Price 21.33 | Shares 1
Sale 7 Jan 2016
Value US$21.33 | Price 21.33 | Shares 1
Sale 7 Jan 2016
Value US$21.33 | Price 21.33 | Shares 1
Sale 7 Jan 2016
Value US$21.33 | Price 21.33 | Shares 1
Planned sale 6 Jan 2016
Value US$1,658.77 | Price 21.54 | Shares 77
Sale 6 Jan 2016
Value US$1,494.02 | Price 21.65 | Shares 69
Sale 6 Jan 2016
Value US$1,487.81 | Price 21.56 | Shares 69
Sale 6 Jan 2016
Value US$46,652.86 | Price 22.30 | Shares 2,092
Sale 6 Jan 2016
Value US$1,486.27 | Price 21.54 | Shares 69
Sale 6 Jan 2016
Value US$1,487.65 | Price 21.56 | Shares 69
Sale 6 Jan 2016
Value US$46,652.86 | Price 22.30 | Shares 2,092
Sale 6 Jan 2016
Value US$1,486.27 | Price 21.54 | Shares 69
Sale 6 Jan 2016
Value US$1,120.21 | Price 21.54 | Shares 52
Planned sale 6 Jan 2016
Value US$52,071.90 | Price 22.30 | Shares 2,335
Sale 6 Jan 2016
Value US$46,652.86 | Price 22.30 | Shares 2,092
Sale 6 Jan 2016
Value US$46,652.86 | Price 22.30 | Shares 2,092
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2018-12-26 2018-12-24 S Sale
Gurney Austin

See Remarks

Officer
47,495 -25.6%
52.20
US$4,213,318 		47,495 -25.6% 52.20 US$4,213,318
2018-10-11 2018-10-10 S Sale Li Yvonne

See Remarks

Officer
48,320 -4.0%
320.79
US$1,028,784 		48,320 -4.0% 320.79 US$1,028,784
2018-10-11 2018-10-10 S Sale Stagg Robert

SVP, Clinical R&D

Officer
92,249 -0.0%
364.93
US$903,219 		92,249 -0.0% 364.93 US$903,219
2018-10-11 2018-10-10 S Sale
Lewicki John A.

President & CEO

Executive Director
1,156 -2.0%
2.01
US$2,324 		1,156 -2.0% 2.01 US$2,324
2018-10-11 2018-10-10 S Sale Hager Alicia J.

SVP & General Counsel

Officer
1,156 -2.2%
2.02
US$2,335 		1,156 -2.2% 2.02 US$2,335
2018-10-11 2018-10-10 S Sale
Gurney Austin

See Remarks

Officer
1,156 -1.5%
2.01
US$2,324 		1,156 -1.5% 2.01 US$2,324
2018-10-10 2018-10-09 S Sale Stagg Robert

SVP, Clinical R&D

Officer
1,686 -3.9%
2.13
US$3,589 		1,686 -3.9% 2.13 US$3,589
2018-10-10 2018-10-09 PlS Planned sale Li Yvonne

See Remarks

Officer
1,229 -2.0%
2.13
US$2,616 		1,229 -2.0% 2.13 US$2,616
2018-10-10 2018-10-09 PlS Planned sale
Gurney Austin

See Remarks

Officer
1,686 -2.1%
2.13
US$3,589 		1,686 -2.1% 2.13 US$3,589
2018-10-10 2018-10-09 PlS Planned sale
Lewicki John A.

President & CEO

Executive Director
2,296 -3.9%
2.13
US$4,888 		2,296 -3.9% 2.13 US$4,888
2018-10-10 2018-10-09 S Sale
Hager Alicia J.

SVP & General Counsel

Officer
1,686 -3.1%
2.13
US$3,589 		1,686 -3.1% 2.13 US$3,589
2018-04-26 2018-04-24 S Sale
Stagg Robert

SVP, Clinical R&D
4,051 -8.6%
2.68
US$10,848 		4,051 -8.6% 2.68 US$10,848
2018-04-26 2018-04-24 S Sale
Lewicki John A.

President & CEO

Executive Director
4,557 -7.6%
2.68
US$12,202 		4,557 -7.6% 2.68 US$12,202
2018-04-26 2018-04-24 S Sale
Gurney Austin

See Remarks
4,051 -5.0%
2.68
US$10,848 		4,051 -5.0% 2.68 US$10,848
2018-04-26 2018-04-24 S Sale Li Yvonne

See Remarks
5,062 -7.8%
2.68
US$13,555 		5,062 -7.8% 2.68 US$13,555
2018-04-26 2018-04-24 S Sale
Hager Alicia J.

SVP & General Counsel
4,051 -6.9%
2.68
US$10,848 		4,051 -6.9% 2.68 US$10,848
2017-10-12 2017-10-10 S Sale
Hager Alicia J.

SVP & General Counsel
1,202 -2.0%
4.24
US$5,099 		1,202 -2.0% 4.24 US$5,099
2017-10-12 2017-10-10 S Sale
Hager Alicia J.

SVP & General Counsel
46 -0.1%
4.26
US$196 		46 -0.1% 4.26 US$196
2017-10-12 2017-10-10 S Sale Patel Sunil

See Remarks
1,202 -1.7%
4.24
US$5,099 		1,202 -1.7% 4.24 US$5,099
2017-10-12 2017-10-10 S Sale
3.9
Patel Sunil

See Remarks
46 -0.1%
4.27
US$196 		46 -0.1% 4.27 US$196
2017-10-12 2017-10-10 S Sale HASTINGS PAUL J

Chairman & CEO
1,346 -1.7%
4.24
US$5,709 		1,346 -1.7% 4.24 US$5,709
2017-10-12 2017-10-10 S Sale
2.8
HASTINGS PAUL J

Chairman & CEO
52 -0.1%
4.26
US$222 		52 -0.1% 4.26 US$222
2017-10-12 2017-10-10 S Sale Gurney Austin

See Remarks
1,202 -1.5%
4.24
US$5,099 		1,202 -1.5% 4.24 US$5,099
2017-10-12 2017-10-10 S Sale
Gurney Austin

See Remarks
46 -0.1%
4.27
US$196 		46 -0.1% 4.27 US$196
2017-10-12 2017-10-10 S Sale
Lewicki John A.

EVP, Research & Development
1,202 -1.7%
4.24
US$5,099 		1,202 -1.7% 4.24 US$5,099
2017-10-12 2017-10-10 S Sale Lewicki John A.

EVP, Research & Development
46 -0.1%
4.26
US$196 		46 -0.1% 4.26 US$196
2017-06-07 2017-06-05 B Purchase KARSEN PERRY A
10,000 +inf%
3.46
US$34,588 		10,000 +inf% 3.46 US$34,588
2017-05-26 2017-05-26 S Sale ROOT JONATHAN D Non-Executive Director
3,222 -100.0%
3.70
US$11,927 		3,222 -100.0% 3.70 US$11,927
2017-05-26 2017-05-26 S Sale ROOT JONATHAN D Non-Executive Director
6,358 -100.0%
3.70
US$23,536 		6,358 -100.0% 3.70 US$23,536
2017-05-26 2017-05-25 B Purchase LASERSOHN JACK W Non-Executive Director
34,614 +22.9%
3.37
US$116,639 		34,614 +22.9% 3.37 US$116,639
2017-05-26 2017-05-24 S Sale ROOT JONATHAN D Non-Executive Director
1,447 -31.0%
3.72
US$5,377 		1,447 -31.0% 3.72 US$5,377
2017-05-26 2017-05-24 S Sale ROOT JONATHAN D Non-Executive Director
2,853 -31.0%
3.72
US$10,601 		2,853 -31.0% 3.72 US$10,601
2017-05-25 2017-05-23 B Purchase LASERSOHN JACK W Non-Executive Director
20,000 +15.3%
3.55
US$71,000 		20,000 +15.3% 3.55 US$71,000
2017-05-22 2017-05-19 S Sale ROOT JONATHAN D Non-Executive Director
2,519 -35.0%
3.70
US$9,324 		2,519 -35.0% 3.70 US$9,324
2017-05-22 2017-05-19 S Sale ROOT JONATHAN D Non-Executive Director
4,968 -35.0%
3.70
US$18,388 		4,968 -35.0% 3.70 US$18,388
2017-05-18 2017-05-16 B Purchase LASERSOHN JACK W Non-Executive Director
23,507 +21.8%
3.49
US$82,061 		23,507 +21.8% 3.49 US$82,061
2017-05-18 2017-05-16 S Sale ROOT JONATHAN D Non-Executive Director
2,321 -24.4%
3.58
US$8,313 		2,321 -24.4% 3.58 US$8,313
2017-05-18 2017-05-16 S Sale ROOT JONATHAN D Non-Executive Director
4,579 -24.4%
3.58
US$16,401 		4,579 -24.4% 3.58 US$16,401
2017-04-05 2017-04-04 S Sale
3.9
Patel Sunil

See Remarks
5,711 -18.9%
9.06
US$51,731 		5,711 -18.9% 9.06 US$51,731
2017-04-05 2017-04-04 S Sale Patel Sunil

See Remarks
43 -0.1%
8.87
US$382 		43 -0.1% 8.87 US$382
2017-04-05 2017-04-04 PlS Planned sale
Hoey Timothy

SVP, Cancer Biology & Co-CSO
5,711 -9.1%
9.06
US$51,731 		5,711 -9.1% 9.06 US$51,731
2017-04-05 2017-04-04 PlS Planned sale
Hoey Timothy

SVP, Cancer Biology & Co-CSO
43 -0.1%
8.87
US$381 		43 -0.1% 8.87 US$381
2017-04-05 2017-04-04 S Sale
Hager Alicia J.

SVP & General Counsel
4,284 -16.6%
9.06
US$38,805 		4,284 -16.6% 9.06 US$38,805
2017-04-05 2017-04-04 S Sale
Hager Alicia J.

SVP & General Counsel
32 -0.1%
8.87
US$284 		32 -0.1% 8.87 US$284
2017-04-05 2017-04-04 PlS Planned sale HASTINGS PAUL J

Chairman & CEO

Executive Director
6,425 -16.5%
9.06
US$58,199 		6,425 -16.5% 9.06 US$58,199
2017-04-05 2017-04-04 PlS Planned sale HASTINGS PAUL J

Chairman & CEO

Executive Director
48 -0.1%
8.87
US$426 		48 -0.1% 8.87 US$426
2017-04-05 2017-04-04 PlS Planned sale
Gurney Austin

See Remarks
5,711 -11.7%
9.06
US$51,731 		5,711 -11.7% 9.06 US$51,731
2017-04-05 2017-04-04 PlS Planned sale
Gurney Austin

See Remarks
43 -0.1%
8.87
US$381 		43 -0.1% 8.87 US$381
2017-04-05 2017-04-04 PlS Planned sale
Lewicki John A.

EVP, Research & Development
5,711 -19.9%
9.06
US$51,731 		5,711 -19.9% 9.06 US$51,731
2017-04-05 2017-04-04 PlS Planned sale Lewicki John A.

EVP, Research & Development
43 -0.1%
8.87
US$381 		43 -0.1% 8.87 US$381
2017-03-17 2017-03-15 PlS Planned sale Hager Alicia J.

SVP & General Counsel
6,652 -20.4%
10.00
US$66,520 		6,652 -20.4% 10.00 US$66,520
2017-01-09 2017-01-06 PlS Planned sale HASTINGS PAUL J

Chairman & CEO

Executive Director
21,369 -36.4%
8.52
US$181,957 		21,369 -36.4% 8.52 US$181,957
2017-01-09 2017-01-05 PlS Planned sale HASTINGS PAUL J

Chairman & CEO

Executive Director
21,369 -36.4%
8.17
US$174,602 		21,369 -36.4% 8.17 US$174,602
2017-01-05 2017-01-03 PlS Planned sale Hoey Timothy

SVP, Cancer Biology & Co-CSO
12,763 -17.3%
7.64
US$97,448 		12,763 -17.3% 7.64 US$97,448
2017-01-05 2017-01-03 PlS Planned sale Lewicki John A.

EVP, Research & Development
9,175 -22.5%
7.63
US$70,045 		9,175 -22.5% 7.63 US$70,045
2016-11-18 2016-11-16 PlS Planned sale Hoey Timothy

SVP, Cancer Biology & Co-CSO

Officer
12,500 -17.0%
9.89
US$123,609 		12,500 -17.0% 9.89 US$123,609
2016-01-12 2016-01-11 PlS Planned sale Dupont Jakob

SVP & Chief Medical Officer

Officer
2,500 -10.8%
20.01
US$50,021 		2,500 -10.8% 20.01 US$50,021
2016-01-08 2016-01-07 S Sale Patel Sunil

See Remarks

Officer
1 -0.0%
21.33
US$21 		1 -0.0% 21.33 US$21
2016-01-08 2016-01-07 S Sale Lewicki John A.

EVP & Chief Scientific Officer

Officer
1 -0.0%
21.33
US$21 		1 -0.0% 21.33 US$21
2016-01-08 2016-01-07 S Sale
Dupont Jakob

SVP & Chief Medical Officer

Officer
1 -0.0%
21.33
US$21 		1 -0.0% 21.33 US$21
2016-01-08 2016-01-07 S Sale Hoey Timothy

SVP, Cancer Biology

Officer
1 -0.0%
21.33
US$21 		1 -0.0% 21.33 US$21
2016-01-08 2016-01-07 S Sale
Gurney Austin

See Remarks

Officer
1 -0.0%
21.33
US$21 		1 -0.0% 21.33 US$21
2016-01-08 2016-01-07 S Sale Hager Alicia J.

VP & General Counsel

Officer
1 -0.0%
21.33
US$21 		1 -0.0% 21.33 US$21
2016-01-08 2016-01-06 PlS Planned sale HASTINGS PAUL J

Chairman & CEO

Executive Director
77 -0.3%
21.54
US$1,659 		77 -0.3% 21.54 US$1,659
2016-01-08 2016-01-06 S Sale Patel Sunil

See Remarks

Officer
69 -0.4%
21.65
US$1,494 		69 -0.4% 21.65 US$1,494
2016-01-08 2016-01-06 S Sale Lewicki John A.

EVP & Chief Scientific Officer

Officer
69 -0.4%
21.56
US$1,488 		69 -0.4% 21.56 US$1,488
2016-01-08 2016-01-06 S Sale Dupont Jakob

SVP & Chief Medical Officer

Officer
69 -0.3%
21.54
US$1,486 		69 -0.3% 21.54 US$1,486
2016-01-08 2016-01-06 S Sale Hoey Timothy

SVP, Cancer Biology

Officer
69 -0.1%
21.56
US$1,488 		69 -0.1% 21.56 US$1,488
2016-01-08 2016-01-06 S Sale Gurney Austin

See Remarks

Officer
69 -0.2%
21.54
US$1,486 		69 -0.2% 21.54 US$1,486
2016-01-08 2016-01-06 S Sale Hager Alicia J.

VP & General Counsel

Officer
52 -0.4%
21.54
US$1,120 		52 -0.4% 21.54 US$1,120
2016-01-08 2016-01-06 PlS Planned sale
2.8
HASTINGS PAUL J

Chairman & CEO

Executive Director
2,335 -9.6%
22.30
US$52,072 		2,335 -9.6% 22.30 US$52,072
2016-01-08 2016-01-06 S Sale
3.9
Patel Sunil

See Remarks

Officer
2,092 -10.5%
22.30
US$46,653 		2,092 -10.5% 22.30 US$46,653
2016-01-08 2016-01-06 S Sale Lewicki John A.

EVP & Chief Scientific Officer

Officer
2,092 -10.5%
22.30
US$46,653 		2,092 -10.5% 22.30 US$46,653
2016-01-08 2016-01-06 S Sale
Dupont Jakob

SVP & Chief Medical Officer

Officer
2,092 -9.2%
22.30
US$46,653 		2,092 -9.2% 22.30 US$46,653
2016-01-08 2016-01-06 S Sale Hoey Timothy

SVP, Cancer Biology

Officer
2,092 -4.2%
22.30
US$46,653 		2,092 -4.2% 22.30 US$46,653
Explore more

More insider trading research around OncoMed Pharmaceuticals Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America